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In this issue of the Journal, McClay and colleagues report on a
clinical trial of adjuvant treatment with cisplatin and tamoxifen in
153 melanoma patients stages II to IV (McClay et al, 2000). This
study has several important limitations, since it is not randomized
and has no control arm. The authors nevertheless suggest a benefi-
cial effect of treatment on disease-free and overall survival. The
design of this trial deserves consideration acknowledging the
information available on adjuvant treatment of melanoma at the
time the study was initiated, and the report needs to be examined
from the perspective of today, the time the study is reported.
QUESTION 1
What was the situation at the time the trial was
instituted?
In 1993, there was no established standard adjuvant treatment for
melanoma patients. The results of the ECOG trial 1684 on high-
dose interferon were not available, and all other randomized
adjuvant treatment trials with chemotherapy as well as biological
agents did not suggest a benefit. The search for adjuvant
treatments was clearly indicated.
For metastatic melanoma, DTIC was the only widely licensed
compound. Cisplatin is another active agent, however, cisplatin-
induced remissions were usually short-lived. Tamoxifen had been
used in non-randomized trials as single agent or in addition to
DTIC or cisplatin-based polychemotherapy. A small randomized
trial reported by Cocconi suggested a survival benefit for patients
with metastatic melanoma, if tamoxifen was added to DTIC
(Cocconi et al, 1992). There was no further information from
randomized studies concerning an effect of tamoxifen in 
addition to chemotherapy, although several uncontrolled phase II
trials suggested a high response rate (however within the confi-
dence limits of other polychemotherapy regimens) of treatment
with chemotherapy and tamoxifen in patients with metastatic
melanoma (DelPrete et al, 1984; McClay et al, 1987). Preclinical
studies from the group of McClay described a synergistic
interaction between cisplatin and tamoxifen (McClay et al, 1993).
In order to study a possible effect of cisplatin and tamoxifen
as adjuvant treatment on survival of melanoma patients, a
randomized controlled adjuvant trial protocol would have been
logical in view of the information available at that time.
Knowing the information available today, there is no remaining
strong rationale to study cisplatin and tamoxifen as adjuvant treat-
ment in melanoma patients. For metastatic melanoma, a larger
randomized study suggested no significant effect of cisplatin
added to a combination of DTIC and vinblastin, although there
was a favourable trend for an improved response-rate and time-
to-progression (Jungnelius et al, 1998). If cisplatin is added to
interferon and interleukin 2, the response-rate and time-to-
progression can be doubled in patients with metastatic melanoma,
but this is again without effect on survival, as shown in a random-
ized EORTC study (Keilholz et al, 1997). Regarding tamoxifen,
two larger randomized studies have proven its inefficiency if
added to cisplatin-containing chemotherapy in advanced
melanoma (Rusthoven et al, 1996; Agarwala et al, 1999). An
important recent ECOG study comparing DTIC single-agent treat-
ment to a combination of DTIC, cisplatin, BCNU and tamoxifen
revealed a (non-significant) doubling in response-rate and no
effect on survival in 240 patients with metastatic melanoma
(Chapman et al, 1999).
QUESTION 2
What type of conclusions is possible from an adjuvant
non-randomized phase II clinical trial?
Uncontrolled open phase II trials are designed to test the activity
and/or the toxicity of a single drug-regimen. Generally a total of
20–50 patients are recruited in these studies. Therefore this design
is acceptable for treatment of patients with measurable disease.
Only in case of new treatment modalities (e.g. vaccines), the proof
of principle with regard to biological end-points should be
assessed in the setting of phase I and II trials. For multidrug
regimens, where the feasibility and activity represent the major
end-points, it is recommended to perform randomized phase II/III
trials. Feasibility of administration of cisplatin and tamoxifen was
not an issue in this study, since, as the authors state themselves,
many hundreds of patients had already received this combination,
and the toxicity is well known. Treatment efficacy would therefore
have been the only reasonable end-point.
McClay and colleagues do not provide a statistical rationale for
their study. As a consequence, 153 patients were enrolled without
justification for the patient number. Furthermore, the interval
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only stated that the scans to exclude further tumour metastases
were to be done within 1 month of initiation of treatment.
Unspecified is the time interval between surgery and enrolment
into the study and no information is provided on the actual interval
between surgery and enrolment. The possible exclusion of early
relapsers might have improved survival as it may have excluded an
adverse prognosis group of patients.
QUESTION 3
What can we learn by comparing survival data from a
non-randomized adjuvant trial to historical controls?
The immediate answer of a statistician would be: nothing! There
are examples in the literature, where survival analyses from
uncontrolled trials in melanoma patients with metastatic disease
were used to define prognostic factors for randomized studies
(e.g. Balch et al, 1983; Ahmann et al, 1989; Creagan et al, 1990;
Barth et al, 1995; Keilholz et al, 1998), or to develop hypotheses,
but these analyses were performed retrospectively, on data from
patients treated within clinical trials performed with another
justification.
Regarding adjuvant treatments, an example on how misleading
survival data from uncontrolled phase II trials can be is the situa-
tion in the field of high-dose chemotherapy for patients with breast
cancer. Comparison of phase II survival information with
historical controls had suggested a survival benefit achieved
with high-dose chemotherapy, however, this was not reproducible
in randomized studies, because in the randomized studies the
survival data of conventional treatment were much better than the
historical controls.
An example regarding the change of control groups over time
even in controlled randomized studies is illustrated in the develop-
ment of adjuvant high-dose interferon treatment for melanoma.
When the ECOG analysed their trial 1690 (Kirkwood et al, 1999),
which had been designed to confirm the trial 1684 (Kirkwood
et al, 1996), the survival curves of the high-dose interferon arms of
both trials were found to be identical. However, the survival curve
of the control group of the 1690 trial was identical to the treatment
group, and significantly better than the control group of the 1684
trial. Numerous factors are being discussed, which may have
caused the improved survival of the control group in the newer
study. As this discussion is ongoing, it is evident that comparison
with historical controls is not appropriate for drawing conclusions
from adjuvant treatment studies.
A third important example is derived from the development of
combination chemotherapy for patients with metastatic melanoma.
It took 15 years from the initial favourable report of the four-
drug regimen DBCT (dacarbacine, BCNU, cisplatin, tamoxifen,
delPrete et al, 1984) to perform the decisive randomized study
proving that this combination did not result in improved survival
in patients with advanced melanoma (Chapman et al, 1999).
However, during these 15 years the DBCT regimen had been
widely adopted on the basis of uncontrolled phase II data.
CONCLUSIONS
There is no evidence that patients with melanoma may benefit
from adjuvant chemotherapy and the report by McClay et al does
not change this situation. This uncontrolled study only shows the
overall outcome, in terms of disease-free survival and survival,
with surgically resected melanoma of stages II, III and IV. The
patients represent a selected patient population, as they all had an
initial performance status of 0 and an unspecified interval between
surgery and initiation of chemotherapy. Such descriptive survival
curves do not allow for any firm conclusions to be made regarding
efficacy of adjuvant therapy. In order to develop efficient treat-
ments for melanoma patients, we should all continue to make
every possible effort to enter patients into controlled adjuvant
trials.
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